Form 4: AbbVie EVP, GC AND SECRETARY Perry C. Siatis Reports Stock Transactions
SEC Form 4
Perry C. Siatis, EVP, GC AND SECRETARY of AbbVie Inc., reports multiple transactions involving AbbVie common stock, including sales and acquisitions through option exercises.
Summary
- On February 28, 2025, Perry C. Siatis disposed of 7,870 shares of AbbVie common stock at $205.02.
- Also on February 28, 2025, Siatis sold 2,718 shares at a weighted average price of $205.38, 6,811 shares at a weighted average price of $206.62, and 363 shares at a weighted average price of $207.19.
- On March 3, 2025, Siatis acquired 2,918 shares at $144.54, 7,315 shares at $149.62, and 7,775 shares at $175.28 through option exercises.
- On March 3, 2025, Siatis sold 18,008 shares at $210.
- Following these transactions, Siatis directly owns 4,619 shares of AbbVie common stock.
- Siatis also holds options to buy 2,918 shares at $144.54, 7,314 shares at $149.62, and 15,549 shares at $175.28.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the insider's trading activity.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of executives and their potential alignment with shareholder interests.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The transactions are related to stock options granted under AbbVie's Amended and Restated 2013 Incentive Stock Program, which is a common practice among large corporations to incentivize executives.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the executive's perspective on the company's stock value.
- The transactions have no immediate impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/17/2023 | Date exercisable for Option (Right to buy) of 2,918 shares |
| 02/16/2024 | Date exercisable for Option (Right to buy) of 7,315 shares |
| 02/15/2025 | Date exercisable for Option (Right to buy) of 7,775 shares |
| 02/28/2025 | Date of multiple transactions involving the sale of AbbVie common stock. |
| 03/03/2025 | Date of multiple transactions involving the acquisition and sale of AbbVie common stock. |
| 03/04/2025 | Date of signature for the Form 4 filing. |
| 02/16/2032 | Expiration date for Option (Right to buy) of 2,918 shares |
| 02/15/2033 | Expiration date for Option (Right to buy) of 7,315 shares |
| 02/14/2034 | Expiration date for Option (Right to buy) of 7,775 shares |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.